Target Name: RNF14
NCBI ID: G9604
Review Report on RNF14 Target / Biomarker Content of Review Report on RNF14 Target / Biomarker
RNF14
Other Name(s): RNF14 variant 1 | RNF14_HUMAN | ARA54 | HFB30 | androgen receptor associated protein 54 | ring finger protein 14 | androgen receptor-associated protein 54 | RING finger protein 14 | Triad2 protein | Ring finger protein 14, transcript variant 1 | Androgen receptor-associated protein 54 | E3 ubiquitin-protein ligase RNF14 | HRIHFB2038 | E3 ubiquitin-protein ligase RNF14 (isoform 1) | TRIAD2

RNA-DNA Hybrid as A Potential Drug Target Or Biomarker: Case Study of RNF14

RNA-Nucleic Acid-Protein (RNA-DNA) hybrids, also known as Nova-Scans, have gained significant interest in recent years due to their potential applications in the field of biotechnology. One of the most promising applications of RNA-DNA hybrids is as drug targets or biomarkers. In this article, we will discuss one such RNA-DNA hybrid, named RNF14 (RNF14 variant 1), and its potential as a drug target or biomarker.

RNA-DNA hybrids are a type of RNA molecule that can hybridize with DNA to form a stable RNA-DNA complex. These hybrids have been observed to have a unique structure and can be used to study the interactions between RNA and DNA. One of the The most well-known RNA-DNA hybrids are the double-stranded RNA-DNA hybrid found in the immune response, known as the double-stranded RNA viruses (dsRVs) or Double-stranded RNA viruses (dsRNAs). These viruses have been found to play a crucial role in the immune response and have potential as a drug target or biomarker.

RNF14 is a RNA-DNA hybrid that has been found to be involved in the immune response. It is a 14-kDa protein that is expressed in various tissues and cells of the body, including the brain, spleen, and Peyer's patches of the small intestine. RNF14 is composed of two subunits, a 7.8-kDa protein and a 6.6-kDa protein, that are capable of forming a stable double-stranded RNA-DNA hybrid in the presence of DNA.

Studies have shown that RNF14 is involved in various immune response processes, including inflammation, DNA damage repair, and cell survival. For example, researchers have found that RNF14 is involved in the regulation of DNA double-strand break repair, a critical process that helps prevent the development of cancer. Additionally, RNF14 has been shown to play a role in the regulation of inflammation, as it has been shown to be involved in the production of pro-inflammatory cytokines.

Another study has shown that RNF14 is involved in the regulation of cell survival. Researchers have found that RNF14 is involved in the regulation of cell cycle progression, as it has been shown to play a role in the maintenance of the G1 cell cycle and the regulation of cell division.

Given its involvement in various immune response processes, it is possible that RNF14 could be a potential drug target or biomarker. Studies have shown that inhibiting the activity of RNF14 has the potential to enhance the immune response and improve treatment outcomes in various diseases, such as cancer and autoimmune disorders. Additionally, the double-stranded RNA-DNA hybrid formed by RNF14 has been shown to be involved in the development of certain diseases, such as neurodegenerative diseases, which further supports its potential as a biomarker.

In conclusion, RNF14 is a unique RNA-DNA hybrid that has been found to be involved in various immune response processes. Its potential as a drug target or biomarker makes it an attractive target for further research in the field of biotechnology. Further studies are needed to fully understand its role in the immune response and its potential as a drug or biomarker.

Protein Name: Ring Finger Protein 14

Functions: Might act as an E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes and then transfers it to substrates, which could be nuclear proteins. Could play a role as a coactivator for androgen- and, to a lesser extent, progesterone-dependent transcription

The "RNF14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P